TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6349289

Group type: EXPERIMENTAL
Intervention: Health motivation treatment (self-management skills, film model, verbal commitment, discussion of costs and benefits)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aversive smoking (normally paced aversive smoking, relaxation training, role playing high risk situations, discussion of maladaptive thought patterns)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Health motivation treatment
Number of subjects: 35
Study: 30308287

Group type: EXPERIMENTAL
Intervention: Daily drinking
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Happiness
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quality of sleep
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercising
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Confidence to cope with pain without medication
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Time spent with a loved one
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coping behavior
Number of subjects: 55
Study: 28888927

Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia
Number of subjects: 3755

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3755
Study: 27094363

Group type: EXPERIMENTAL
Intervention: Collaborative Strategic Reading (CSR) instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of CSR instruction
Number of subjects: 0
Study: 25364993

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Interoceptive Cues (CBT‐IC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 78
Study: 23140210

Group type: EXPERIMENTAL
Intervention: Intervention group (insertion of written ID recommendations in clinical records)
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Complete adherence to ID recommendations
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Adequate initial treatment
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Non-adherence to recommendations
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Charlson index
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Nosocomial infection
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 1173
Study: 19355795

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone propionate combination (SFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17706002

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 0
Study: 15008689

Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nicotine abstinence
Number of subjects: 130
Study: 11156770

Group type: EXPERIMENTAL
Intervention: Enhancing lesions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: New enhancing lesions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: New black holes
Number of subjects: 50
Study: 9090787

Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 18

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 18
Study: 8490328

Group type: EXPERIMENTAL
Intervention: 200 IU of nasal salmon calcitonin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 24
Study: 2825508

Group type: COMPARATOR
Intervention: CTC-VCR (Vincristine)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CTC-VDS (Vindesine)
Number of subjects: 116
Study: 29425304

Group type: EXPERIMENTAL
Intervention: Serum P1NP (N‐terminal propeptide of type‐1 collagen)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Serum CTX (C‐telopeptide of type‐1 collagen)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Serum 1‐CTP (pyridinoline cross‐linked carboxy‐terminal telopeptide of type‐1 collagen)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: High baseline P1NP (>70 ng/mL)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: High baseline CTX (>0.299 ng/mL)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: High baseline 1‐CTP (>4.2 ng/mL)
Number of subjects: 872

Group type: COMPARATOR
Intervention: None of the markers
Number of subjects: 872
Study: 27552061

Group type: EXPERIMENTAL
Intervention: 5 g resveratrol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23890368

Group type: EXPERIMENTAL
Intervention: Sub-Tenon injection of 2.5 ml of 2% lidocaine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intra‐cameral lidocaine 1%
Number of subjects: 71
Study: 22790243

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard endovascular techniques (control)
Number of subjects: 21
Study: 20035493

Group type: EXPERIMENTAL
Intervention: Caloric restriction + resistance training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 137
Study: 18544974

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) + 2 g of galacto-oligosaccharides (GOS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactobacillus GG (LGG) alone (6.5 x 10(9) CFU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG + GOS
Number of subjects: 30
Study: 15924355

Group type: EXPERIMENTAL
Intervention: Vaginal surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Abdominal surgery
Number of subjects: 82
Study: 14556322

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Beclomethasone and loratidine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Loratidine alone
Number of subjects: 92
Study: 12721247

Group type: EXPERIMENTAL
Intervention: Idarubicin and ara‐C (IA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Troxacitabine and ara‐C (TA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Troxacitabine and idarubicin (TI)
Number of subjects: 34
Study: 9536920

Group type: EXPERIMENTAL
Intervention: Vitamin E, 400 i.u. daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine (10 mg/min) administration
Number of subjects: 20
Study: 7705152

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure therapy (N-CPAP) at a pressure of 10 cm H2O
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recumbent posture without N-CPAP
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Upright posture without N-CPAP
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Upright posture with N-CPAP
Number of subjects: 7

Group type: COMPARATOR
Intervention: Any posture change or N-CPAP
Number of subjects: 7
Study: 2705667

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (0.1 mg/kg, repeated every 15 minutes up to three doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Meperidine with dimenhydrinate (0.4 mg/kg meperidine and 25 mg dimenhydrinate, repeated every 15 minutes up to three doses)
Number of subjects: 46
Study: 336647

Group type: EXPERIMENTAL
Intervention: Biofeedback Induced Anxiety
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Conventional Induced Anxiety
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 21
Study: 31257407

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure goal (<120 mm Hg)
Number of subjects: 9323

Group type: COMPARATOR
Intervention: Standard systolic blood pressure goal (<140 mm Hg)
Number of subjects: 9323
Study: 29282031

Group type: EXPERIMENTAL
Intervention: Standard argument plus narrative message
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Standard argument plus inoculation message
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control (non-advocacy based message)
Number of subjects: 6000
Study: 26790259

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil treatment once a week
Number of subjects: 199

Group type: COMPARATOR
Intervention: Self-healing (control group)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil treatment
Number of subjects: 199
Study: 23392989

Group type: EXPERIMENTAL
Intervention: Folinic acid supplementation
Number of subjects: 10
Study: 21441884

Group type: EXPERIMENTAL
Intervention: Electrical auricular acupuncture (AA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrodes only (placebo)
Number of subjects: 40
Study: 19366542

Group type: EXPERIMENTAL
Intervention: Group II - pumping warm saline into the abdomen until it spilled out of the open ports
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group I - evacuation of residual CO(2) by abdominal oppression
Number of subjects: 40
Study: 16404275

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 34

Group type: COMPARATOR
Intervention: Triamcinolone (Control)
Number of subjects: 34
Study: 15309242

Group type: EXPERIMENTAL
Intervention: Amiodarone (group Ia)
Number of subjects: 144
Study: 11386980

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (100 microgram)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9255002

Group type: EXPERIMENTAL
Intervention: Early cord clamping (n = 48)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Late cord clamping (n = 59)
Number of subjects: 107
Study: 8290211

Group type: EXPERIMENTAL
Intervention: Modified trabeculotomy ab externo (TAB), n = 44
Number of subjects: 79

Group type: COMPARATOR
Intervention: Trabeculectomy with adjunctive mitomycin C (TMC), n = 35
Number of subjects: 79
Study: 3297772

Group type: EXPERIMENTAL
Intervention: Serum albumin loss, intestinal plasma loss (measured by intestinal alpha 1-antitrypsin clearance), occurrence of inflammatory cells (leukocytes) in feces.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Leakage of antileukoprotease from the respiratory tract into the blood.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of current grading system and SAL (serum albumin loss).
Number of subjects: 31
Study: 31035497

Group type: EXPERIMENTAL
Intervention: Higher Dietary Diversity Score (DDS) quartile
Number of subjects: 6587

Group type: COMPARATOR
Intervention: Lowest Dietary Diversity Score (DDS) quartile
Number of subjects: 6587
Study: 28585394

Group type: EXPERIMENTAL
Intervention: Wii-based exercise program (n = 14), 2-month duration, 3 sessions per week, including training games for aerobic endurance, balance, and isometric strength
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Wii-based exercise program (n = 14)
Number of subjects: 27
Study: 26338348

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 95
Study: 23445920

Group type: EXPERIMENTAL
Intervention: Bench Press (BP) exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Leg Press (LP) exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both BP and LP exercises
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation between CK peaks after LP and BP
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Agreement of classification between exercises
Number of subjects: 42
Study: 22027646

Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f) for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no micronutrient supplementation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f) in male subjects
Number of subjects: 40
Study: 18648875

Group type: EXPERIMENTAL
Intervention: ProMIS laparoscopic simulator
Number of subjects: 160
Study: 18218204

Group type: EXPERIMENTAL
Intervention: HNPPV group (n=20) with conventional therapy and HNPPV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20) with conventional therapy only
Number of subjects: 40
Study: 14767751

Group type: EXPERIMENTAL
Intervention: Vitamin A (180,000 IU a day before HDMTX)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) only
Number of subjects: 35
Study: 11834237

Group type: EXPERIMENTAL
Intervention: Sodium cellulose sulfate (CS), 7 consecutive daily doses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonoxynol-9 (Conceptrol), active control
Number of subjects: 36
Study: 9568181

Group type: EXPERIMENTAL
Intervention: Mistletoe lectin (ML-1) standardized therapy; subcutaneous administration of 0.5-1.0 ng ML-1/kg body weight, twice a week
Number of subjects: 0
Study: 8309029

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) niacin at 1500 mg/d and above
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) niacin at 1500 mg/d and above
Number of subjects: 46

Group type: COMPARATOR
Intervention: Immediate-release (IR) niacin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sustained-release (SR) niacin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both IR and SR niacin
Number of subjects: 46
Study: 3058614

Group type: EXPERIMENTAL
Intervention: Gastroplasty
Number of subjects: 57

Group type: COMPARATOR
Intervention: Very-Low-Calorie Diet (VLCD)
Number of subjects: 57
Study: 17894065

Group type: EXPERIMENTAL
Intervention: LSD (lysergic acid diethylamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DA (dextroamphetamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LSD and DA
Number of subjects: 0
Study: 29614865

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Relapsed ITP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prednisolone in relapsed subgroup
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 75
Study: 27629581

Group type: EXPERIMENTAL
Intervention: Risk Reduction Therapy for Adolescents (RRTA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual Services (US)
Number of subjects: 105
Study: 26702161

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23134807

Group type: EXPERIMENTAL
Intervention: Special Olympics Unified Sports soccer training program (8 weeks, 1.5 hours per session, three times per week)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison group (CG) without specific training
Number of subjects: 46
Study: 20673994

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for adolescents with mental health problems; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 18325242

Group type: EXPERIMENTAL
Intervention: PriMa program (school-based prevention program for anorexia nervosa)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Questionnaires used in the evaluation
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Program user feedback
Number of subjects: 1006
Study: 16523251

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 416
Study: 14503430

Group type: EXPERIMENTAL
Intervention: Continuous gastric feeding
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intermittent gastric feeding
Number of subjects: 45
Study: 11885182

Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Non-HA-coated implants
Number of subjects: 2900
Study: 8703169

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units, subcutaneously every 12 hours)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin, 30 mg, subcutaneously every 12 hours)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 344
Study: 1411449

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3890872

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg b.d. for 3 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 10
Study: 29746232

Group type: EXPERIMENTAL
Intervention: AboutFace (web-based video gallery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational booklet about PTSD treatment
Number of subjects: 60
Study: 30268456

Group type: EXPERIMENTAL
Intervention: Pulmonary nodules group (nodule group)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Normal CT group
Number of subjects: 338
Study: 26842751

Group type: EXPERIMENTAL
Intervention: Exit interviews conducted on days of consultations
Number of subjects: 19579
Study: 24912463

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral treatment with motivational support
Number of subjects: 262

Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral treatment without motivational support
Number of subjects: 262
Study: 21771277

Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐84) at 0.5‐5.0 μg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single doses of rhPTH(1‐84) at 1.0, 2.0, and 4.0 μg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multiple doses of rhPTH(1‐84) at 2.0 μg/kg once daily for 7 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multiple doses of rhPTH(1‐34) at 2.0 μg/kg once daily for 7 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-dosing at 4 hr
Number of subjects: 32
Study: 20677916

Group type: EXPERIMENTAL
Intervention: Prolieve System
Number of subjects: 34

Group type: COMPARATOR
Intervention: Targis System
Number of subjects: 34
Study: 17391172

Group type: EXPERIMENTAL
Intervention: Low-dose tri-iodothyronine (T3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15604153

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 11444997

Group type: EXPERIMENTAL
Intervention: Active therapeutic ultrasound
Number of subjects: 35
Study: 9133749

Group type: EXPERIMENTAL
Intervention: alprazolam 2 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: alprazolam 6 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: imipramine 225 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 7962327

Group type: EXPERIMENTAL
Intervention: rhIL-6 infusion (150 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rhIL-6 administered sc for 42 consecutive days (150 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 3673933

Group type: EXPERIMENTAL
Intervention: Gambian meal of rice with groundnut sauce
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 0
Study: 29304544

Group type: EXPERIMENTAL
Intervention: Prior preterm birth
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Prior term birth
Number of subjects: 653
Study: 25637070

Group type: EXPERIMENTAL
Intervention: Wish intervention (granting a wish)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 26289497

Group type: EXPERIMENTAL
Intervention: Sativex (9‐delta‐tetrahydrocannabinol plus cannabidiol) oromucosal spray for 4 weeks (including 2 weeks' titration)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 4 weeks (including 2 weeks' titration)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sativex and Placebo
Number of subjects: 34
Study: 23698747

Group type: EXPERIMENTAL
Intervention: FLAG3-Ro60(K170A R174A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLAG3-Ro60(H187S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mY3 RNA interference in wild-type fibroblasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mY1 RNA interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of mY1 in mY3-depleted fibroblasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Y RNA in an in vitro model of anti-Ro60-mediated injury
Number of subjects: 0
Study: 19881358

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/d) added to UDCA
Number of subjects: 8
Study: 18955671

Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) positive patients
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) negative patients
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: TWA testing overall
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: TWA-negative patients
Number of subjects: 490
Study: 16640105

Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin-alpha1 (1.6 microg three times per week) and lymphoblastoid interferon (5 MIU three times per week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Monotherapy with lymphoblastoid interferon (5 MIU three times per week)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Combination therapy and monotherapy
Number of subjects: 98
Study: 14674810

Group type: EXPERIMENTAL
Intervention: Assigned purpose goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adopted purpose goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congruent mastery-approach goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral purpose goal context (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent purpose goals
Number of subjects: 0
Study: 10905766

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0